China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other ...

GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

GlaxoSmithKline (GSK) has announced full results from the Salford Lung Study (SLS), a pioneering study of COPD treatment aimed at creating a clinical trial much closer to everyday clinical practice.

GSK has also just received CHMP recommendation ... with the continent's top five markets also being vitally important. Trelegy also has a COPD triple therapy competitor approved in Europe, where ...

In COPD, patients with abnormally high exertional breathlessness on CPET are unlikely to be identified via standard symptom ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment ...

GSK hosted the third annual RespiVerse meeting on December 13-14 in Bangkok, Thailand, bringing together renowned ...

COPD affects more than 390 million people globally and over 14 million people in the US. GSK noted that recurrent exacerbations add to pressures on healthcare systems, and the COPD -related ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for ...